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Abstract
Background: The primary objective was to describe infectious complications in children with acute myeloid leukemia from
presentation to the healthcare system to initiation of chemotherapy and to describe how these infections differ depending
on neutropenia.
Methods: We conducted a retrospective, population-based cohort study that included children and adolescents with acute
myeloid leukemia diagnosed and treated at 15 Canadian centers. We evaluated infections that occurred between
presentation to the healthcare system (for symptoms that led to the diagnosis of acute myeloid leukemia) until initiation of
chemotherapy.
Results: Among 328 children, 92 (28.0%) were neutropenic at presentation. Eleven (3.4%) had sterile-site microbiologically
documented infection and four had bacteremia (only one Gram negative). Infection rate was not influenced by neutropenia.
No child died from an infectious cause prior to chemotherapy initiation.
Conclusion: It may be reasonable to withhold empiric antibiotics in febrile non-neutropenic children with newly diagnosed
acute myeloid leukemia until initiation of chemotherapy as long as they appear well without a clinical focus of infection.
Future work could examine biomarkers or a clinical score to identify children presenting with leukemia and fever who are
more likely to have an invasive infection.
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present.[3] The optimal management of children with newly
diagnosed leukemia with fever in the period preceding initiation of
chemotherapy is uncertain, both for those with and without
neutropenia. Cancer-specific fever and neutropenia guidelines do
not provide recommendations for this scenario since the setting for
guidelines is usually restricted to patients who are receiving
treatments for cancer.[2,4] Furthermore, it would be useful to
know if infection outcomes differed depending on the presence or
absence of neutropenia in this setting since the presence of

Introduction
Children with acute myeloid leukemia (AML) receive intensive
chemotherapy and during treatment, they are at substantial risk of
morbidity and mortality from invasive infections.[1] The management of fever with neutropenia is relatively straightforward in
these children after they begin chemotherapy.[2] However, when
children with acute leukemia initially enter the healthcare system,
fever is a common presentation and neutropenia may also be
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neutropenia is a major criterion that influences the decision to start
antibiotics in febrile children receiving treatment for cancer.
Consequently, we conducted a population-based study of
pediatric AML using a retrospective cohort design. The primary
objective was to describe infectious complications in children with
AML from presentation to the healthcare system to initiation of
chemotherapy and to describe how these infections differ
depending on neutropenia.

presence of suspected or proven infection and organ dysfunction.[8] Clinically documented infections were classified based
upon the Centers for Disease Control and Prevention (CDC)
definitions of nosocomial infections.[9] However, for our study, we
did not require that clinically documented infections be not
present or incubating at the time of admission to hospital. Fever of
unknown origin was fever occurring in the absence of a positive
microbiology result or clinical site of infection.

Materials and Methods

Potential Predictors
We compared baseline characteristics and infection outcomes
depending upon if the patient was neutropenic (absolute neutrophil count (ANC),0.56109/L) at presentation.
Characteristics evaluated were: gender, age, Down syndrome,
body mass index percentile at diagnosis, peripheral blood counts at
diagnosis and AML morphology. Obesity was defined as body
mass index (BMI) $95th percentile and underweight was defined
as BMI #10th percentile for age and gender according to the
CDC for those at least 2 years of age.[10] BMI was evaluated as
obesity previously has been associated with treatment-related
mortality and infections in pediatric AML[11,12].

Ethics Statement
This study was approved by the Research Ethics Board at The
Hospital for Sick Children and local Research Ethics Boards of the
14 other participating sites (McMaster University-Hamilton
Health Sciences/Faculty of Health Sciences Research Ethics
Board, Montreal Children’s Hospital Research Ethics Board,
Children’s Hospital of Eastern Ontario Research Ethics Board,
University of Winnipeg Research Ethics Board, University of
British Columbia/Children’s and Women’s Health Centre of
British Columbia Research Ethics Board, Centre Hospitalier
Universitaire Sainte-Justine Research Ethics Board, University of
Calgary Conjoint Health Research Ethics Board, IWK Research
Ethics Board, Queen’s University-Health Sciences Research
Ethics Board, University of Western Ontario Research Ethics
Board for Health Science Research Involving Human Subjects,
Memorial University Human Investigation Committee, Centre
Hospitalier Universitaire de Quebec Research Ethics Board,
University of Alberta Health Research Ethics Board-Biomedical
Panel, and Centre Hospitalier Universitaire de Sherbrooke
Research Ethics Board). As this was a retrospective review study,
the Research Ethics Board at The Hospital for Sick Children and
those at the 14 other participating sites waived the need for written
informed consent. All demographic information and information
about the child’s diagnosis and treatment were abstracted from the
child’s chart.

Statistics
Characteristics and infection outcomes were compared between
those who were and were not neutropenic at presentation using
the Wilcoxon rank sum test for continuous variables and Chi
square or Fisher’s exact test for categorical variables. All tests of
significance were two-sided, and statistical significance was defined
as P,0.05. Statistical analysis was performed using the SAS
statistical program (SAS-PC, version 9?3; SAS Institute Inc., Cary,
NC).

Results
There were 343 children with de novo AML who met eligibility
criteria in the study time frame. Of these children, 15 began
chemotherapy on the same day as presentation to the healthcare
center and thus, there were 328 children with pre-chemotherapy
information available. The median time between presentation and
initiation of chemotherapy was 2 (range 0 to 274) days. There were
two patients who had very lengthy delays between presentation
and initiation of chemotherapy of 59 and 274 days.
Table S1 illustrates that 92 (28.0%) children were neutropenic
at presentation. Gender and age were not significantly associated
with neutropenia at presentation whereas children with Down
syndrome were significantly less likely to present with neutropenia.
Children with neutropenia had a significantly lower initial
peripheral blast count and hemoglobin level compared to nonneutropenic children although the initial platelet count was similar
between the two groups.
Table 1 and Table S2 illustrate the infection outcomes. Overall,
there were 11/328 (3.4%) children who experienced 12 sterile site
microbiologically documented infections; the risk did not significantly differ by the presence or absence of neutropenia. There
were four episodes of bacteremia with viridans group streptococci
(n = 3) and Pseudomonas aeruginosa (n = 1), all occurring in nonneutropenic children. Among the six episodes of urinary tract
infection, the causative agents were: Enterococcus species (n = 2),
Escherichia coli (n = 2), P. aeruginosa (n = 1) and Candida albicans
(n = 1). The two other sterile site infections were Staphylococcus
aureus from a peritoneal drain (see below) and a lymph node
biopsy. Other than for the one C. albicans urinary tract infection,
no other fungi from sterile or non-sterile sites were observed (data

Study Sample
This manuscript is related to a large retrospective, populationbased cohort study in which we included children and adolescents
with AML diagnosed and treated in each Canadian province
except Saskatchewan.[5] We included children and adolescents
#18 years with de novo AML diagnosed between January 1, 1995
and December 31, 2004. Children with Down syndrome were also
included. We excluded those with acute promyelocytic leukemia,
secondary AML, and previous diagnosis of immunodeficiency.

Outcome Measures
We evaluated infections that occurred between presentation to
the healthcare system (for symptoms that led to the diagnosis of
AML) until initiation of chemotherapy. Data abstraction was
conducted by trained clinical research associates who travelled to
each site to abstract and code all data.
We described the occurrence of sterile site invasive infection[6],
clinically documented infection and fever of unknown origin.
Fever was defined as a single oral temperature of 38.3u C or a
temperature of 38.0u C for 1 hour.[7] In this study, we did not
distinguish between infections present at the time of admission and
those acquired after admission but prior to initiation of treatment.
Positive cultures with common contaminants such as coagulase
negative Staphylococcus were only considered true infection if there
were two or more positive cultures in the same episode or if the
infection was associated with sepsis. In this study, sepsis was
defined as systemic inflammatory response syndrome in the
PLOS ONE | www.plosone.org
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Table 1. Infection outcomes before chemotherapy initiation by neutropenia at presentation.*

Neutropenic at
Presentation (N = 92)

Not Neutropenic at
Presentation (N = 236)

P Value

Median days of fever (range)

1.0 (0.0–17.0)

1.0 (0.0–16.0)

0.794

Sterile site microbiologically documented infection (%)

2 (2.2)

9 (3.8)

0.734

Gram-positive sterile site infection (%)

1 (1.1)

6 (2.5)

0.678

Gram-negative sterile site infection (%)

1 (1.1)

3 (1.3)

1.000

Bacteremia (%)a

0

4 (1.7)

0.580

Invasive fungal infection (%)

1 (2.2)

0

0.281

Clinically documented infection (%)

12 (13.0)

31 (13.1)

1.000

Fever of unknown origin (%)

35 (38.0)

86 (36.4)

0.886

Median days intravenous antibiotics (range)

1.0 (0.0–16.0)

0.0 (0.0–25.0)

0.073

Sepsis (%)

1.0 (1.1)

0

0.281

Infection-related mortality (%)

0

0

NC

Abbreviation: NC–not calculable.
*Infection outcomes denote at least one occurrence during the pre-chemotherapy period.
a
Bacteremias were viridans group streptococci (n = 3) and Pseudomona aeruginosa (n = 1).
doi:10.1371/journal.pone.0061899.t001

not shown). One child experienced sepsis with concurrent
pneumonia.
Three children died before initiation of chemotherapy. Two
children died of hyperleukocytosis and pulmonary leukostasis. A
third child presented with a 10 day history of fever and was found
to have pneumonia on chest radiograph; the absolute neutrophil
count was 0.26109/L at presentation. The child was treated with
broad-spectrum antibiotics and after 10 days of persistent fever,
she was found to have C. albicans from urine and therefore,
amphotericin B was initiated. Over the next four days, she
developed acute respiratory distress and multi-organ failure; a
peritoneal drain grew S. aureus. Autopsy failed to reveal an
infectious cause of death and death was attributed to progressive
AML.

unwell appearance or a clinical site of infection), broad-spectrum
antibiotics with activity against P.aeruginosa are important.
Future work could examine biomarkers or a clinical score to
identify children presenting with leukemia and fever who are more
likely to have an invasive infection. This approach may allow
antibiotic therapy to be tailored to children at higher risk of
infection.
The strengths of our report are the multi-center nature of the
study which allowed capture of a large number of children with
AML. Further, the data are highly generalizable. However, there
are important limitations to our study. Centers had different
approaches to supportive care and urgency of chemotherapy
initiation. Second, the retrospective design made it more difficult
to appreciate the clinical status of the child at presentation.
In conclusion, we found that in children with AML, 28% will
present with neutropenia. Sterile site infections were rare. It may
be reasonable to withhold empiric antibiotics in febrile nonneutropenic children with newly diagnosed AML until initiation of
chemotherapy as long as they appear well without a clinical focus
of infection.

Discussion
We conducted a comprehensive assessment of infections
occurring before chemotherapy initiation in newly diagnosed
pediatric AML. We found that sterile site infections were rare,
Gram negative bacteremia occurred in only one child, and many
infections were from a urinary site. Infection outcomes were
similar between neutropenic and non-neutropenic children. Our
findings suggest that it may be reasonable to withhold empiric
antibiotics in febrile non-neutropenic children with newly diagnosed AML until initiation of chemotherapy as long as they
appear well without a clinical focus of infection. Reducing
antibiotic exposure is important given the relationship between
greater antibiotic use and antibiotic resistance[13,14] and invasive
fungal infection.[15] However, the safety of this approach has not
yet been tested.
Although our analysis did not show a difference in outcomes by
neutropenia at presentation, limited power for this comparison is
an important consideration since only 28% of children were
neutropenic. Patients with non-cancer related neutropenia may be
at risk of invasive infection if the neutropenia is associated with
profound immunosuppression.[16] Thus, we do not suggest
withholding empiric antibiotics in this situation and suggest
empiric antibiotics be initiated in a febrile neutropenic child with
newly diagnosed AML. Our data also suggest that if empiric
antibiotics are initiated (for example, because of neutropenia,
PLOS ONE | www.plosone.org
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